This British Association for Psychopharmacology guideline replaces the original version published in 2010, and contains updated information and recommendations.
This guideline covers recognising, assessing and treating mental health problems in women who are planning to have a baby, are pregnant, or have had a baby or been pregnant in the past year.
This guideline covers the short-term management of violence and aggression in adults (aged 18 and over), young people (aged 13 to 17) and children (aged 12 and under).
This guideline covers diagnosing and treating delirium in people aged 18 and over in hospital and in long-term residential care or a nursing home.
Chugai Pharmaceutical Co., Ltd. announced that it has obtained regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) for Piasky for Injection 340 mg (generic name: crovalimab (genetical recombination)) (hereafter, Piasky) , a pH-dependent binding humanized anti-complement (C5) monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
It aims to improve the care people receive by detailing the most effective treatments for anorexia nervosa, binge eating disorder and bulimia nervosa.
The FDA has approved Ultomiris (ravulizumab) injection, from Alexion Pharmaceuticals, for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria...
The British Association for Psychopharmacology guidelines for the treatment of substance abuse, harmful use, addiction and comorbidity with psychiatric disorders...
Voydeya (danicopan) has been approved in Japan for the treatment of paroxysmal nocturnal haemoglobinuria (PNH).
The FDA has approved Nocdurna (desmopressin acetate sublingual tablets; Ferring) for the treatment of nocturia due to nocturnal polyuria in...